Local treatment of prostate cancer

Expert-Guided Poster Tour 15

**Monday 18 March**

**13:30 - 15:30**

**Location:** Green Area, Room B

**Chairs:**
A. Lamb, Oxford (GB)
D. Tilki, Hamburg (DE)

The Expert-Guided Poster Tour is an innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. Poster viewing of 30 minutes after which two experts, will ask questions to individuals and groups of poster presenters.

**14:00 - 14:03**

**Introduction**
A. Lamb, Oxford (GB)
D. Tilki, Hamburg (DE)

**PT373**
The effect of US Preventive Services Task Force’s screening recommendation on trifecta and pentafecta outcomes in robot-assisted laparoscopic prostatectomy based on analysis of a single-surgeon series

By: Bhat K.R.S¹, Onol F.¹, Rogers T.¹, Jenson C.¹, Rocco B.M.C.², Patel V.¹

¹Global Robotic Institute, Dept. of Urology, Celebration, United States of America,
²University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy

Aims and objectives of this presentation
PT373

**PT374**
The changing face of surgically treated low-risk prostate cancer (PCa): A national cancer database (NCDB) analysis

By: Fotouhi A.¹, Borchert A.², Dalela D.², Sood A.², Keeley J.², Arora S.², Trinh Q-D.³, Peabody J.O.², Menon M.², Abdollah F.²

¹Wayne State University, School of Medicine, Detroit, United States of America,
²Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America,
³Harvard Medical School, Dept. of Surgery, Boston, United States of America

Aims and objectives of this presentation
PT374

**PT375**
Relationship between socioeconomic factors and non-prostate cancer mortality after radical prostatectomy

By: Fröhner M.¹, Farahzadi S.¹, Koch R.¹, Hübler M.², Wirth M.P.¹
PT375

The EORTC quality of life questionnaire predicts long-term overall survival in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort

By: De Nunzio C.1, Pastore A.L.2, Lombardo R.1, Nacchia A.1, Carbone A.2, Fuschi A.2, Dutto L.3, Witt J.H.3
1Sapienza University of Rome, Sant’Andrea Hospital, Dept. of Urology, Rome, Italy, 2Sapienza University of Rome, ICOT Latina Hospital, Dept. of Urology, Latina, Italy, 3St. Antonius Hospital, Dept. of Urology, Paediatric Urology and Urological Oncology, Gronau, Germany

Aims and objectives of this presentation
PT375

PT376

Long-term survival rates of localized prostate cancer patients treated by radical prostatectomy are significantly better than predicted life expectancy of the general population

By: Sakai Y.S., Soma T., Nakamura Y., Aoki Y., Fukui N., Kageyama Y.
Saitama Cancer Center, Dept. of Urology, Ina, Japan

Aims and objectives of this presentation
PT376

PT377

Identification of multi-stakeholder value in prostate cancer treatment by application of Multi-Criteria Decision Making (MCDM)

By: Jorissen P.1, Moons K.1, Pintelon L.1, De Ridder D.2, Everaerts W.2
1KU Leuven, Dept. of Mechanical Engineering, Leuven, Belgium, 2KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium

Aims and objectives of this presentation
PT377

PT378

Gleason grade grouping: The significance of primary Gleason 5 in patients with Gleason grade group 5

By: Tilki D.1, Preisser F.2, Huland H.1, Graefen M.1, Chun F.2, Mandel P.2
1University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, 2University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany

Aims and objectives of this presentation
PT378
<table>
<thead>
<tr>
<th>PT380</th>
<th>Development of a procedure-specific classification system for reporting postoperative complications in prostate cancer patients undergoing robot-assisted radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy, University Hospital “Ospedali Riuniti”, Unit of Urology, Milan, Italy</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

**PT380**

<table>
<thead>
<tr>
<th>PT381</th>
<th>Opioid use before and after radical prostatectomy: Nationwide population-based study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Cazzaniga W., Loeb S., Garmo H., Robinson D., Stattin P.</td>
</tr>
<tr>
<td></td>
<td>IRCCS Ospedale San Raffaele, Uppsala University, Division of Experimental Oncology, Unit of Urology URI, Milan, Italy, New York University and Manhattan Veterans Affairs Medical Center, Dept. of Urology and Population Health, New York, United States of America, Regional Cancer Centre Uppsala Orebro, Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, Ryhov Hospital, Dept. of Urology, Jonköping, Sweden, Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

**PT381**

<table>
<thead>
<tr>
<th>PT382</th>
<th>Fewer days of workplace absenteeism with robotic radical prostatectomy compared to open radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Pucheril D.T., Chen X., Krimphove M.J., Tully K.H., Fletcher S.A., Dasgupta P., Trinh Q-D.</td>
</tr>
<tr>
<td></td>
<td>Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

**PT382**

<table>
<thead>
<tr>
<th>PT383</th>
<th>Hot or cold: No difference in long-term potency between touch-cautery and athermic suture-ligation in control of pedicle during robot-assisted radical prostatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>By: Hofmann M., Huynh L., Skarecky D., Ahlering T.</td>
</tr>
<tr>
<td></td>
<td>University of California, Irvine, Dept. of Urology, Orange, United States of America</td>
</tr>
</tbody>
</table>

**Aims and objectives of this presentation**

**PT383**
PT384  
A novel nomogram to predict lymph node invasion among patients with clinically localized prostate cancer based on clinical and mpMRI parameters: The importance of ECE score. Results from a single center series


IEO, European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, IEO, European Institute of Oncology IRCCS, Dept. of Radiology, Milan, Italy

Aims and objectives of this presentation

PT384

PT385  
Prostate capsule extension: Can we plan surgical treatment based on MRI findings? An analysis of predictive factors to better identify T3a before surgery

By: Regis L., Cuadras M., Miret E., Salazar A., Planas J., Celma A., Lorente D., Maast R., Roche S., Semidey M.E., De Torres M.I., Trilla E., Morote J.

Vall d'Hebron Hospital, Dept. of Urology, Barcelona, Spain, Vall d'Hebron Hospital, Dept. of Radiology, Barcelona, Spain, Vall d'Hebron Hospital, Dept. of Pathology, Barcelona, Spain

Aims and objectives of this presentation

PT385

PT386  
Impact of focal versus whole-gland therapy for prostate cancer in sexual function and urinary continence


Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, Hospital Israelita Albert Einstein, Dept. of Urology, São Paulo, Brazil

Aims and objectives of this presentation

PT386

PT387  
Higher free testosterone predicts faster potency recovery after robot assisted radical prostatectomy

By: El-Khatib F., Huynh L., Towe M., Yafi F., Ahlering T.
University of California, Irvine, Dept. of Urology, Orange, United States of America

Aims and objectives of this presentation

PT387

PT388  
Long-term outcomes and patterns of recurrence in patients with clinical lymphadenopathies undergoing radical prostatectomy as part of a multimodal treatment
Aims and objectives of this presentation
PT388

Extended lymph node dissection is associated with improved overall survival in patients with very high-risk prostate cancer: A national cancer database analysis

By: Sood A., Keeley J., Arora S., Dalela D., Jeong W., Rogers C., Peabody J., Menon M., Abdollah F.
Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America

Aims and objectives of this presentation
PT389

TRoMbone: Testing radical prostatectomy in men with oligo metastatic prostate cancer that has spread to the bone - a randomized controlled feasibility trial

1University College London Hospital, Dept. of Uro-Oncology, London, United Kingdom, 2Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 3Oxford University Hospital, Dept. of Urology, Oxford, United Kingdom, 4Guy's Hospital, Dept. of Urology, London, United Kingdom, 5Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, 6Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom

Aims and objectives of this presentation
PT390

Impact of timing on radiation therapy adverse events following radical prostatectomy, an analysis of the RTOG 9601 cohort

1Henry Ford Hospital, Health System, Dept. of Urology, Detroit, United States of America, 2Harvard Medical School, Dept. of Urology, Boston, United States of America

Aims and objectives of this presentation
PT391

Barriers to selective referral of genitourinary cancers to high- vs. low-volume hospitals

PT392
By: Berg S.¹, Pucheril D.T.¹, Sahraoui A.¹, Tan W.S.², Krimphove M.J.¹, Marchese M.¹, Lipsitz S.R.³, Noldus J.⁴, Kibel A.S.¹, Trinh Q-D.¹
¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, ²University College London, Division of Surgery and Interventional Science, Dept. of Urology, London, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, Massachusetts, United States of America, ⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and NeuroUrology, Herne, Germany

Aims and objectives of this presentation
PT392

**PT393**

Retzius sparing robotic assisted radical prostatectomy: Beyond the learning curve - “Warts 'n all”

Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom

Aims and objectives of this presentation
PT393

**PT394**

Does combined anterior and posterior reconstruction improve early continence in robotic assisted radical prostatectomy?

By: Stanowski M., Lobo N., Petrides N., Kommu S., Eddy B.
Kent and Canterbury Hospital, East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom

Aims and objectives of this presentation
PT394

**PT395**

Hormone therapy for prostate cancer increases the risk of new-onset hypertension: A nationwide propensity score-matched four-year longitudinal cohort study

By: Tseng S., Shiao-Jin S., Wen-Jeng W., Ching-Chia C., Jhen-Hao J.
Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung City, Taiwan

Aims and objectives of this presentation
PT395

**PT396**

The impact of initial PSA <100 ng/mL on prognosis in patients with metastatic hormone naïve prostate cancer (mHNPC)

By: Suzuki Y.¹, Hatakeyama S.¹, Yamamoto H.¹, Imai A.¹, Yoneyama T.¹, Hashimoto Y.¹, Koie T.², Ohyama C.¹
¹Hirosaki University, Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Gifu University, Graduate School of Medicine, Dept. of Urology, Gifu, Japan
Aims and objectives of this presentation
PT396

PT397

**Androgen deprivation treatment (ADT) in the contemporary management of prostate cancer: Real life practice patterns vs. guidelines**

By: Mitropoulos D., Chlosta P., Häggman M., Ström T., Markussis V.

1National and Kapodistrian University of Athens Medical School, Dept. of Urology, Athens, Greece, 2Jagiellonian University, Dept. of Urology, Krakow, Poland, 3Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden, 4Ipsen Sweden, Medical Department, Stockholm, Sweden, 5Ipsen Greece, Medical Department, Athens, Greece

Aims and objectives of this presentation
PT397